ATRX and central nervous system cancer: Frontal lobe IDH1/2-mutant gliomas were characterized by frequent TERTp mutations (51.9%), TP53 mutations (48.1%), 1p/19q co-deletion (45.5%), CIC mutations (34.2%), and ATRX mutations (31.2%) (Fig. 5K).